Stuttgart – The Aenova Group signed an agreement with the owners of Haupt Pharma Group in mid-October to acquire a majority of the the group. Aenova is a significant player in the pharmaceutical and healthcare sector. Haupt Pharma AG specialises in development and con-tract manufacturing for the pharmaceutical industry. By acquiring Haupt Pharma, the Aenova Group has gained a partner with which it can expand its portfolio strategically. The transaction is currently awaiting approval from the competition authorities.
An international team led by Hamburg-based M&A partner Dr Jacob Siebert advised Aenova and majority shareholder BC Partners on all aspects of the due diligence and contract negotia-tions. CMS Hasche Sigle was supported by CMS law firms in Italy, France, Switzerland, Aus-tria and Luxembourg and by World Law Group partner firm City-Yuwa Partners.
BC Partners acquired the Aenova Group in September 2012 from the previous owners, Bridgepoint, adding the Temmler Group shortly afterwards. Almost a year after its successful acquisition of the Temmler Group, annual sales of the Aenova Group rose on completion by around 60% to more than EUR 750 million. A team including Dr Udo Simmat, Dr Tobias Schneider and Dr Jacob Siebert also advised on all aspects of these previous transactions
- CMS Hasche Sigle
Dr Udo Simmat, M&A/Private Equity
Dr Jacob Siebert, Lead Partner, M&A/Private Equity
Johannes Braun, M&A/Due Diligence
Dr Nils Maack, M&A
Stefan Lüft, Pharma
Dr Jakob Steiff, Regulatory
Dr Eva-Maria Burkard, Regulatory
Beate Engin, Regulatory
Dr Antje-Kathrin Uhl, Employment
Dr Tobias Polloczek, Employment/Pensions
Dr Jan Dombrowski, IP
Bernhard Freund, IT
Dr Marc Seibold, Finance
Dr Andreas Grunert, Finance
Dr Andreas Heim, Commercial
Dr Stefan Voss, Real Estate
Dr Harald Kahlenberg, Competition
Dr Hannes Schwinn, Competition
Dr Olaf Thießen, M&A/Tax - CMS Adonnino Ascoli & Cavasola Scamoni (Milan/Rome)
Pietro Cavasola, M&A, Corporate
Serena Carroli, Due Diligence - CMS Bureau Francis Lefebvre (Paris)
Anne-Laure Villedieu, Regulatory/Pharma
Jacques Isnard, Corporate/M&A
Maité Ollivier, Employment - CMS von Erlach Henrici (Zurich)
Dr Kaspar Landolt, Finance - CMS DeBacker Luxembourg
Vivian Walry, Finance - CMS Reich-Rohrwig Hainz (Vienna)
Bernt Elsner, Competition - City-Yuwa Partners (Tokyo)
Mikio Tanaka, Corporate/Due Diligence
Akira Nagasaki, Corporate/Due Diligence
For further information, please contact:
Nicolas Merigeau, NewCap
nmerigeau@newcap.fr
+33 1 44 71 94 98
CMS Bureau Francis Lefebvre
Florence Jouffroy, Directeur du Marketing et de la Communication
Laetitia Mostowski, Responsable Communication externe
florence.jouffroy@cms-bfl.com
laetitia.mostowski@cms-bfl.com
+33 1 47 38 40 32 / 40 74
Social Media cookies collect information about you sharing information from our website via social media tools, or analytics to understand your browsing between social media tools or our Social Media campaigns and our own websites. We do this to optimise the mix of channels to provide you with our content. Details concerning the tools in use are in our privacy policy.